|
|
|
|
||
Buy
Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX The drop in price is not likely due to Intellia's news. Rather, more likely due to KalVista's news about the Phase II results for their oral treatment for HAE which looks like a direct competitor to Orladeyo |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
12750 | Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX | moegrabbedmythumb | 1 | 7/1/2021 4:49:09 PM |